Results 221 to 230 of about 93,504 (350)

Apparent Mineralocorticoid Excess Syndrome: Case Report

Saad Aqeel Alsaadoun, Ameinah Alrasheedi, Seham Hossny Gazar, Ghadah Abdulrahman Alsallum   +3 more
openalex   +2 more sources

Baseline characteristics in the SYNCHRONIZE™‐2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP‐1 receptor dual agonist, for obesity in people with type 2 diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1490-1498, February 2026.
Abstract Aims Survodutide is an investigational glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist that has shown promise for treating obesity and its complications in Phase 2 trials. Two double‐blind, randomized, global Phase 3 trials are designed to assess the efficacy and safety of survodutide for treatment of obesity—SYNCHRONIZE™‐1 in ...
Sean Wharton, Carel W. le Roux, Biykem Bozkurt, Elke Platz, Gabriele Bleckert, Samina Ajaz Hussain, Martina Brueckmann, Elena Startseva, Isabel M. Kloer, Lee M. Kaplan   +9 more
wiley   +1 more source

The Role of Aldosterone in Detecting Resistance-Driven Hypoaldosteronism and Deficit-Driven Hypoaldosteronism. [PDF]

J Clin Med
Ruiz-Sánchez JG, Calle-Pascual AL, Rubio-Herrera MÁ, De Miguel Novoa P, Gómez-Hoyos E, Runkle I.   +5 more
europepmc   +1 more source

Effects of SGLT2 inhibitors across the spectrum of albuminuria in cardiovascular–kidney–metabolic conditions: A pooled analysis of randomised trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1105-1115, February 2026.
Abstract Background Albuminuria is associated with an increased risk of cardiovascular and kidney events. Sodium glucose co‐transporter 2 inhibitors (SGLT2i) reduce albuminuria and improve kidney outcomes in patients with albuminuric chronic kidney disease (CKD).
João Pedro Ferreira, Pedro Marques, Stefan D. Anker, Javed Butler, Gerasimos Filippatos, Abhinav Sharma, Francisco Vasques‐Nóvoa, Luís Mendonça, João Sérgio Neves, Milton Packer, Faiez Zannad   +10 more
wiley   +1 more source

Unmasking Isolated Glucocorticoid Deficiency: Clinical Insights From 2 Cases. [PDF]

JCEM Case Rep
Singhal A, Menon JC, Yadav SC, Gupta A, Sriharsha G, Bhatia E.   +5 more
europepmc   +1 more source

Glucocorticoid and mineralocorticoid receptors regulate paracellular permeability in a primary cultured gill epithelium [PDF]

, 2011
Scott P. Kelly, Helen Chasiotis
openalex   +1 more source

Efficacy and safety of glucagon‐like peptide 1 receptor agonists across all health outcomes in type 2 diabetes: An umbrella review and evidence map of randomised controlled trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1136-1149, February 2026.
Abstract Aim Glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) have been established as effective treatments for type 2 diabetes, offering benefits beyond glycaemic control; however, their associations across multiple health outcomes remain insufficiently assessed.
Dongjin Yeo, Yeona Jo, Jinyoung Jeong, Yi Deun Jeong, Ho Geol Woo, Yejun Son, Sunyoung Kim, Sang Youl Rhee, Dong Keon Yon   +8 more
wiley   +1 more source

Comparing the Long-Term Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors Versus Mineralocorticoid Receptor Antagonists as Add-On Therapies in the Management of Heart Failure: A Systematic Review. [PDF]

Cureus
George V, Pillai MH, Jacob V, Mp R, Vasant A, Adnan H.   +5 more
europepmc   +1 more source

Emerging methods for subtype differentiation in primary aldosteronism

Journal of Internal Medicine, Volume 299, Issue 2, Page 178-195, February 2026.
Abstract Primary aldosteronism (PA) is a common cause of hypertension. Compared to patients with essential hypertension, untreated PA is associated with a two‐ to fourfold greater risk of cardiovascular disease, renal failure, and death. PA is caused by increased secretion of aldosterone from one adrenal gland in 30% of the patients and both adrenal ...
Oskar Ragnarsson, C. Christofer Juhlin, Tobias Åkerström, Per Dahlqvist, Henrik Falhammar, Per Hellman   +5 more
wiley   +1 more source

Renin-guided therapy with mineralocorticoid receptor antagonists in primary aldosteronism: feasibility study (RETAME-PA) - a clinical research protocol for a randomised controlled trial. [PDF]

BMJ Open
Merabtine A, Leung AA, Kline GA, Dubrofsky L, Hundemer GL, Goupil R.   +5 more
europepmc   +1 more source